Quarterly ResultMay 7, 2026, 09:07 AM
Lipocine LPCN 1154 PPD Phase 3 Fails Primary Endpoint; Q1 Net Loss $3.7M
AI Summary
Lipocine Inc. announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. The Phase 3 trial for LPCN 1154 (oral brexanolone) for postpartum depression did not meet its primary endpoint, failing to show a statistically significant reduction in HAM-D score compared to placebo. However, the drug demonstrated a differentiated safety profile, and a post hoc analysis showed significant HAM-D reductions in patients with a history of psychiatric conditions. The company reported a net loss of $3.7 million for the quarter, an increase from $1.9 million in the prior year, while cash and equivalents rose to $24.7 million.
Key Highlights
- LPCN 1154 Phase 3 trial for Postpartum Depression (PPD) did not meet its primary endpoint.
- LPCN 1154 was well-tolerated with no serious adverse events or excessive sedation.
- Post hoc analysis showed statistically significant HAM-D reductions in patients with a history of psychiatric conditions (n=54).
- Lipocine applied for breakthrough therapy and fast track designations for LPCN 1154 in PPD.
- Net loss for Q1 2026 was $3.7 million, compared to $1.9 million in Q1 2025.
- Royalty revenue from TLANDO sales was $119,000 in Q1 2026, up from $94,000 in Q1 2025.
- Research and development expenses increased to $2.8 million in Q1 2026 from $1.1 million in Q1 2025.
- Unrestricted cash, cash equivalents, and marketable securities totaled $24.7 million as of March 31, 2026.